Detail akcie Immupharma online

Business Summary: ImmuPharma PLC is a specialist drug discovery and development company. The Company is engaged in the development of drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases with high medical need. Its lead program, P140, is a non-immunosuppressing, convenient and safe peptide treatment for autoimmune disease, which is in late-stage development for the treatment of systemic lupus erythematosus (SLE) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB is an advanced anti-infective candidate. It is an improved form of amphotericin-B (AMB), a systemic antifungal drug. BioCin is an improved form of vancomycin, a systemic antibacterial which is highly effective against Methicillin-resistant Staphylococcus Aureus (MRSA) and orally against Clostridium Difficile infections.
Financial Summary: BRIEF: For the six months ended 30 June 2025, ImmuPharma PLC revenues was not reported. Net loss applicable to common stockholders increased from L388K to L1.8M. Higher net loss reflects Finance Costs increase from L3K to L743K (expense), Administrative expenses increase of 90% to L491K (expense), Research and development expenses increase of 46% to L690K (expense).